We give a new life and purpose for the old drug, anagrelide, with targeted GIST therapy


Sartar Therapeutics is developing a new therapeutic option for GIST patients based on drug reformulation and repositioning of anagrelide, the drug that has been used to treat thrombocytemia, a blood disease characterized by platelet overproduction. Anagrelide will be reformulated into a slow-release drug product. Reformulation will improve pharmacokinetic properties of the candidate product to make it more efficacious, better tolerated and more convenient for use in therapy.